Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Karen Lutrick, Patrick Rivers, Young M. Yoo, Lauren Grant, James Hollister, Krystal Jovel, Sana Khan, Ashley Lowe, Zoe Baccam, Hanna Hanson, Lauren E.W. Olsho, Ashley Fowlkes, Alberto J. Caban-Martinez, Cynthia Porter, Sarang Yoon, Jennifer Meece, Manjusha Gaglani, Joy Burns, Julie Mayo Lamberte, Flavia Nakayima MiiroAdam Bissonnette, Lindsay LeClair, Preeta K. Kutty, James K. Romine, Elisha Stefanski, Laura J. Edwards, Katherine Ellingson, Joe K. Gerald, Edward J. Bedrick, Purnima Madhivanan, Karl Krupp, Lynn B. Gerald, Mark Thompson, Jefferey L. Burgess

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

What is already known about this topic? The Pfizer-BioNTech COVID-19 vaccine has been shown to be effective in preventing SARS-CoV-2 infection in adolescents in randomized placebo-controlled Phase III trials. What is added by this report? A prospective cohort of 243 adolescents aged 12–17 years in Arizona completed weekly SARS-CoV-2 testing by nasal swab for 19 consecutive weeks. Under real-world conditions, vaccine effectiveness of full immunization (completion of the second in a 2-dose series ≥14 days earlier) was 92% against SARS-CoV-2 infections irrespective of symptom status. What are the implications for public health practice? In real-world conditions among adolescents aged 12–17 years, the Pfizer-BioNTech vaccine was highly effective in preventing SARS-CoV-2 infection.

Original languageEnglish (US)
Pages (from-to)1761-1765
Number of pages5
JournalMorbidity and Mortality Weekly Report
Volume70
Issue number5152
DOIs
StatePublished - 2021

ASJC Scopus subject areas

  • Epidemiology
  • Health(social science)
  • Health, Toxicology and Mutagenesis
  • Health Information Management

Fingerprint

Dive into the research topics of 'Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021'. Together they form a unique fingerprint.

Cite this